- Red Light Holland (TRIP) has received the second report for its psilocybin truffles
- The report was prepared by Shaman Pharma Corp. and CCrest Laboratories Inc. under a Health Canada Controlled Drugs & Substances license
- The report focused on perfecting the truffles’ potency by identifying variables such as water content and size
- Now that a precise and specific analysis method has been determined, Red Light Holland and Shaman Pharma will take next steps to test its robustness and accuracy
- Red Light Holland is an Ontario-based corporation engaged in the production, growth and of a premium brand of magic truffles
- Shares in Red Light Holland Corp. (TRIP) are currently down 6.90 per cent, trading at $0.135 per share
Red Light Holland (TRIP) has received the second report for its psilocybin truffles from a Health Canada-approved laboratory.
The report was prepared by Shaman Pharma Corp. and CCrest Laboratories Inc. under a Health Canada Controlled Drugs & Substances license and focused on perfecting the potency of the truffles.
Identifying variables such as water content and size that have the potential to influence the amount and characteristics of the active ingredients—psilocybin and psilocin—in the truffles, is the first step toward creating a standardized dose from naturally occurring psychoactive truffles.
The report suggests that size is not affecting the concentrations of psilocybin and psilocin, but the water content is an essential factor.
During testing, the laboratory was successfully able to bring the raw material to its anhydrous state while maintaining the same ratio of active ingredients.
“We are learning through market research and anecdotal movements that many people prefer naturally occurring psilocybin over synthetics,” said Red Light Holland CEO Todd Shapiro, “so it’s exciting that Red Light Holland with the help of Shaman Pharma are […] adding to the scientific knowledge of these natural products.”
Now that a precise and specific analysis method has been determined, Red Light Holland and Shaman Pharma will test its robustness and accuracy.
Future analysis will also expand the research using scientific methods applied in pharmaceutical drug development such as performing stability studies under various conditions. This information will allow Red Light Holland to develop lab-scale production projects that will provide practitioners with quality-controlled psilocybin for their patients.
“The progress we have made in the year 2021 was simply groundbreaking which positioned our companies to start this new year with incredible momentum,” remarked Shaman Pharma CEO and president of CCrest Laboratories Alex Grenier.
Red Light Holland is an Ontario-based corporation engaged in the production, growth and of a premium brand of magic truffles.
Shares in Red Light Holland Corp. (TRIP) are currently down 6.90 per cent, trading at $0.135 per share as of 12:44 pm EST.